CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
Penn and CHOP researchers want to develop urea cycle disorder treatments using CRISPR gene-editing therapy. Get unlimited access to Inquirer.com and The Inquirer App, plus 5 articles each month to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback